Biocytogen is dedicated to the development of novel antibody drugs to meet the unmet medical needs, with a particular focus on oncology, autoimmune, inflammatory, metabolic, and other diseases.
The company's assets includes more than 10 assets including monoclonal antibodies, bispecific antibodies, bispecific ADCs, etc. By advancing its R&D capabilities and striving for clinical excellence, Biocytogen aims to deliver transformative therapies to patients in need.
| Therapeutic Area |
Product Candidate |
Target(s) | Molecular Format | Mono/Combo Therapy |
Indication(s) |
|
Rights | Partner |
| Oncology | YH001 | CTLA-4 | mAb | PD-1 | Solid tumors |
|
Global | - |
| Mono | Solid tumors |
|
||||||
| YH002 | OX40 | mAb | YH003+ YH001 |
Intratumoral injection |
|
- | Syncromune | |
| YH003 | CD40 | mAb | PD-1+ chemo |
Pancreatic ductal adenocarcinoma (1L&2L) |
|
Global | - | |
| PD-1+ chemo |
Mucosal melanoma |
|
||||||
| PD-1+ YH001 |
Solid tumors |
|
||||||
| YH004 | 4-1BB | mAb | Mono | Solid tumors |
|
Global | - | |
| YH008 | PD-1 x CD40 |
BsAb | Mono | Solid tumors |
|
ex-Greater China |
Chipscreen NewWay | |
| BCG011 | TROP2 x EGFR |
BsADC | Mono | Solid tumors |
|
- | DOMA | |
| YH013 | EGFR x MET |
BsADC | Mono | Solid tumors |
|
- | DOMA | |
| BCG012 | HER3 x MUC1 |
BsADC | Mono | Solid tumors |
|
- | DOMA |
